Table 2.
Synopsis of the Crosstalk between miRNA and lncRNA for neovascularization
| Cancer type |
Type of Pre-clinical | Mechanism | Type of miRNA | Type of lncRNA | Cellular Changes | Therapeutic intervention for tumor regression | Cellular Signaling | Ref. |
|---|---|---|---|---|---|---|---|---|
| Hepatocellular carcinoma | In vitro | Sponging | Let-7 | CCAT1 | Cellular proliferation | knockdown of CCAT1 inhibited HCC | HMGA2, c-Myc | [76] |
| Glioma | In vitro | NA | miR-34a-5p | TUG1 | Cellular proliferation | NA | VEGF-A | [77] |
| Glioma | In vitro | NA | miR-140 | H19 | Cellular proliferation | knockdown of H19 inhibited glioma | NA | [78] |
| Glioma | In vitro | Sponging | miR-186 | PVT1 | Cellular proliferation, migration |
Overexpression of PVTI and miR-186 provides novel targets for glioma anti-angiogenic Therapy |
NA | [79] |